In an open-label, multicenter, multicohort study that included 90 patients with relapsed or refractory follicular lymphoma who had received at least two prior lines of systemic therapy, 60% of patients receiving treatment with mosunetuzumab-axgb achieved a complete response and 80% had an overall response. On December 22, 2022, the U.S. Food and Drug Administration granted mosunetuzumab-axgb accelerated approval based on those findings.

Nearly 60% of patients with cancer turn to herbal supplements for symptom relief, but patient-physician communication about that use remains inadequate. Unsupervised herbal use can lead to adverse events and herb-drug interactions for patients during active treatment. Many physicians and providers also lack sufficient knowledge about herbal supplements to help patients make informed decisions.

Although 74%–84% of patients with breast cancer who undergo mastectomies are satisfied with their bodies and outcomes after electing to have a flat closure, 20%–35% say that they felt unsupported by their cancer care team during the process. Patients report feeling marginalized or stigmatized, not being told that flat closure is an option, and even left with excess skin against their wishes because the care team wanted to give them “future options.”

The expansion of oral chemotherapy agents since 2000 has transformed the treatment landscape. More than 150 novel oral anticancer medications are currently U.S. Food and Drug Administration approved, with new agents continuously in the pipeline. When caring for patients who are taking oral therapies, oncology nurses and pharmacists can work together to handle drug refills, deliver patient education, and manage the entire treatment cycle—including adverse events.

Under the U.S. Food and Drug Administration’s (FDA’s) fast-track approval process, nadofaragene firadenovec-vncg (Adstiladrin®) became the first gene therapy approved for the treatment of high-risk non-muscle invasive bladder cancer. Approximately 75% of newly diagnosed bladder cancers are classified as non-muscle invasive. Bacillus Calmette Guérin has been used as first-line therapy for more than 20 years, but eventually 30%–50% of patients stop responding, and nadofaragene firadenovec-vncg offers a new treatment option. FDA’s December 2022 approval was based on complete response (CR) and duration of response from Study CS-003, which demonstrated a 46% CR for at least one year.